Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Pfizer reported results that beat analyst forecasts for the second quarter, but its COVID-19 vaccine partner BioNTech posted results that missed expectations amid weaker demand for updated shots, underscoring how uneven vaccination demand continues to shape earnings momentum across the sector.
THE APEX TIMES
THE APEX TIMES
A Yahoo Finance market note points to a shift in Pfizer’s (PFE) valuation picture, arguing the stock’s longer-term underperformance is no longer paired with the same degree of perceived “cheap” or “expensive” pricing.
THE APEX TIMES
A market commentary highlighted Pfizer’s dividend pull and valuation alongside hopes for a late-stage obesity drug, arguing the stock’s narrative gap is keeping some investors on the sidelines.
THE APEX TIMES
A market watch post circulated among Zacks.com users on July 31 highlighted Pfizer (PFE) as a “trending” stock, pointing readers to what the shares could be indicating going forward. The post itself, however, does not provide detailed new fundamentals in the material available here.
THE APEX TIMES
A fresh cluster of European Commission approvals this week adds to the region’s evolving drug landscape, including updates affecting Pfizer’s and BioNTech’s vaccine portfolio and Incyte’s skin cancer and inflammatory pipeline.
THE APEX TIMES
A new Yahoo Finance look at Pfizer’s upcoming results for the quarter ended June 2026 urges investors to judge the quarter using more than analysts’ expected earnings and revenue figures.
THE APEX TIMES
The drugmaker says its once-daily LITFULO met positive topline readouts across two Phase 3 trials in patients with both active and stable nonsegmental vitiligo, though details of efficacy and safety were not included in the initial report.
THE APEX TIMES
The European Commission granted approval for an updated, XFG-adapted COVID-19 vaccine from Pfizer and BioNTech, covering use in people aged 6 months and older across the European Union for the upcoming seasonal rollout.
THE APEX TIMES
A market preview from Yahoo Finance says Pfizer (PFE) appears to have the right mix of factors to outperform analyst expectations when it releases second-quarter results, though the post offers limited details on the underlying drivers.
